Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy.
Original Source of Genzyme and Isis Report Results of Two Phase 3 Trials of Mipomersen
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that a Luxembourg incorporated wholly-owned subsidiary of Shire plc will launch a voluntary public takeover offer for all the shares in Movetis NV, the Belgium-based European specialty gastrointestinal (GI) company.
Original Source of Shire Proposes to Expand Specialist…
EU-funded researchers have developed a new defence against infection from the AIDS (acquired immune deficiency syndrome) virus. The pioneering method involves creating a protective shield that restricts the virus from making contact with a susceptible host cell and penetrating the immune system.
Original Source of Scientists launch new attack against…
Revenue in the second quarter increased by 1 percent at CER, but was up 3 percent on an actual basis as a result of the positive impact of exchange rate movements.
Original Source of AstraZeneca Second Quarter and Half Year Results 2010
Drugmakers are always dealing with regulators. If it’s not the patent office or the FDA, it’s customs officials and the like. But national security?
Safeguards to protect patients from risky drugs should have less paperwork and more consistency, drugmakers and pharmacy representatives said this week during an FDA meeting. Report
Original Source of FDA hears critics on risk-management programs
The Provenge data published in this week’s New England Journal of Medicine might not be new. It has, after all, been presented at a conference and submitted to FDA in support of the newly approved prostate cancer vaccine. But the study is now down in black-and-white–under the auspices of…
Nature abhors a vacuum, and apparently Novartis does, too. The Swiss drugmaker is leaping into the void created by Johnson & Johnson’s ( NYSE: JNJ ) big children’s drug recall by introducing its own children’s pain reliever and fever reducer ahead of schedule. And it’s giving the new product…
Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).
Original Source of FDA Grants Priority Review to Cladribine Tablets
The U.K.’s cost-effectiveness watchdog has given the final nod to a trio of cancer drugs–Roche’s Xeloda and MabThera, and AstraZeneca’s Iressa–which means the NHS must provide funding and resources for them in the next three months. Report
Original Source of NICE opens door to Roche, AZ cancer drugs